E Fund Management Co. Ltd. Has $303,000 Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

E Fund Management Co. Ltd. cut its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 34.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,934 shares of the company’s stock after selling 1,007 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Krystal Biotech were worth $303,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in KRYS. Janney Montgomery Scott LLC raised its position in shares of Krystal Biotech by 17.1% in the 3rd quarter. Janney Montgomery Scott LLC now owns 37,047 shares of the company’s stock valued at $6,744,000 after buying an additional 5,415 shares in the last quarter. TimesSquare Capital Management LLC grew its holdings in shares of Krystal Biotech by 37.6% during the 3rd quarter. TimesSquare Capital Management LLC now owns 114,222 shares of the company’s stock valued at $20,792,000 after purchasing an additional 31,183 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in shares of Krystal Biotech by 25.8% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 2,186 shares of the company’s stock valued at $398,000 after purchasing an additional 449 shares during the last quarter. Prime Capital Investment Advisors LLC grew its holdings in shares of Krystal Biotech by 93.1% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 2,591 shares of the company’s stock valued at $472,000 after purchasing an additional 1,249 shares during the last quarter. Finally, Oppenheimer Asset Management Inc. bought a new stake in shares of Krystal Biotech during the 3rd quarter valued at approximately $235,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Krystal Biotech Price Performance

KRYS opened at $179.93 on Friday. Krystal Biotech, Inc. has a fifty-two week low of $141.72 and a fifty-two week high of $219.34. The firm has a market capitalization of $5.18 billion, a price-to-earnings ratio of 60.18 and a beta of 0.87. The company’s 50 day moving average price is $161.18 and its two-hundred day moving average price is $174.57.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same period in the previous year, the firm posted $0.30 EPS. The company’s revenue for the quarter was up 116.4% compared to the same quarter last year. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Insider Activity

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares of the company’s stock, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Citigroup lifted their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a report on Thursday, February 20th. Chardan Capital lifted their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a report on Thursday, February 20th. HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Finally, Jefferies Financial Group started coverage on shares of Krystal Biotech in a report on Wednesday. They set a “buy” rating and a $245.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $220.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).